The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Activating a collaborative innate-adaptive immune response to control metastasis
Open accessAbstract
Many cancers recruit monocytes/macrophages and polarize them into tumor-associated macrophages (TAMs). TAMs promote tumor growth and metastasis and inhibit cytotoxic T cells. Yet, macrophages can also kill cancer cells after polarization by e.g. , lipopolysaccharide (LPS, a bacteria-derived toll-like receptor 4 [TLR4] agonist) and interferon gamma (IFNγ). They do so via nitric oxide (NO), generated by inducible NO synthase (iNOS). Altering the polarization of macrophages could therefore be a strategy for controlling cancer. Here, we show that monophosphoryl lipid A (MPLA, a derivative of LPS) with IFNγ activated macrophages isolated from metastatic pleural effusions of breast cancer patients to kill the corresponding patients’ cancer cells in vitro . Importantly, intratumoral injection of MPLA with IFNγ not only controlled local tumor growth but also reduced metastasis in mouse models of luminal and triple negative breast cancers. Furthermore, intraperitoneal administration of MPLA with IFNγ reprogrammed peritoneal macrophages, suppressed metastasis, and enhanced the response to chemotherapy in the ID8-p53 −/− ovarian carcinoma mouse model. The combined MPLA+IFNγ treatment reprogrammed the immunosuppressive microenvironment to be immunostimulatory by recruiting leukocytes, stimulating type I interferon signaling, decreasing tumor-associated (CD206 + ) macrophages, increasing tumoricidal (iNOS + ) macrophages, and activating cytotoxic T cells through macrophage-secreted interleukin 12 (IL-12) and tumor necrosis factor α (TNFα). Both macrophages and T cells were critical for the anti-metastatic effects of MPLA+IFNγ. MPLA and IFNγ are already used individually in clinical practice, so our strategy to engage the anti-tumor immune response, which requires no knowledge of unique tumor antigens, may be ready for near-future clinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
Stuehr, D. J., & Nathan, C. F. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.169.5.1543 · Cited by 1,744
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice
Albrengues, J., Shields, M. A., Ng, D., Park, C. G., Ambrico, A., Poindexter, M. E., Upadhyay, P., Uyeminami, D. L., Pommier, A., Küttner, V., et al. (2018) · Science · doi:10.1126/science.aao4227 · Cited by 1,476
Self-citationEfficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Xie, Q. W., Whisnant, R., & Nathan, C. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1779 · Cited by 1,118
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25
Yang, L., Liu, Q., Zhang, X., Liu, X., Zhou, B., Chen, J., Huang, D., Li, J., Li, H., Chen, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2394-6 · Cited by 965
Targeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
The role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2526 · Cited by 920
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 919
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Nitric oxide metabolism and breakdown
Kelm, M. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00020-1 · Cited by 673
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov245 · Cited by 593
Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor
Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., Chmielowski, B., Staddon, A. P., Cohn, A. L., Shapiro, G. I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411366 · Cited by 582
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
Self-citationNeutrophils facilitate ovarian cancer premetastatic niche formation in the omentum
Lee, W., Ko, S. Y., Mohamed, M. S., Kenny, H. A., Lengyel, E., & Naora, H. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181170 · Cited by 478
Role of interferon regulatory factor 1 in induction of nitric oxide synthase.
Martin, E., Nathan, C., & Xie, Q. W. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.3.977 · Cited by 477
Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
Wiemann, B., & Starnes, C. O. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90023-x · Cited by 467
Collagen density regulates the activity of tumor-infiltrating T cells
Kuczek, D. E., Larsen, A. M. H., Thorseth, M.-L., Carretta, M., Kalvisa, A., Siersbæk, M. S., Simões, A. M. C., Roslind, A., Engelholm, L. H., Noessner, E., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0556-6 · Cited by 435
Yin, M., Li, X., Tan, S., Zhou, H. J., Ji, W., Bellone, S., Xu, X., Zhang, H., Santin, A. D., Lou, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87252 · Cited by 417
Mehta, A. K., Gracias, D. T., & Croft, M. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.003 · Cited by 404
Marim, F. M., Silveira, T. N., Lima, D. S., & Zamboni, D. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015263 · Cited by 351
Engelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., & Krummel, M. F. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.008 · Cited by 330
Self-citationInflammatory breast cancer biology: the tumour microenvironment is key
Lim, B., Woodward, W. A., Wang, X., Reuben, J. M., & Ueno, N. T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0010-y · Cited by 326
Toll-Like Receptor Agonists in Cancer Therapy
Adams, S. (2009) · Immunotherapy · doi:10.2217/imt.09.70 · Cited by 310
Self-citationGao, J., Morrison, D. C., Parmely, T. J., Russell, S. W., & Murphy, W. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.2.1226 · Cited by 303
Arwert, E. N., Harney, A. S., Entenberg, D., Wang, Y., Sahai, E., Pollard, J. W., & Condeelis, J. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.007 · Cited by 263
Pozzi, L.-A. M., Maciaszek, J. W., & Rock, K. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2071 · Cited by 259
Walton, J., Blagih, J., Ennis, D., Leung, E., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 237
Self-citationWang, S., Campos, J., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 231
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Self-citationAckerman, S. E., Pearson, C. I., Gregorio, J. D., Gonzalez, J. C., Kenkel, J. A., Hartmann, F. J., Luo, A., Ho, P. Y., LeBlanc, H., Blum, L. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00136-x · Cited by 213
Salim, T., Sershen, C. L., & May, E. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153289 · Cited by 210
Cole, A. J., Dwight, T., Gill, A. J., Dickson, K.-A., Zhu, Y., Clarkson, A., Gard, G. B., Maidens, J., Valmadre, S., Clifton-Bligh, R., et al. (2016) · Scientific Reports · doi:10.1038/srep26191 · Cited by 208
Lung inflammation promotes metastasis through neutrophil protease-mediated degradation of Tsp-1
El Rayes, T., Catena, R., Lee, S., Stawowczyk, M., Joshi, N., Fischbach, C., Powell, C. A., Dannenberg, A. J., Altorki, N. K., Gao, D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507294112 · Cited by 207
Dinapoli, M. R., Calderon, C. L., & Lopez, D. M. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1323 · Cited by 204
Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis
Kaczanowska, S., Beury, D. W., Gopalan, V., Tycko, A. K., Qin, H., Clements, M. E., Drake, J., Nwanze, C., Murgai, M., Rae, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.048 · Cited by 203
Cassetta, L., & Kitamura, T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00038 · Cited by 200
Ovarian cancer creates a suppressive microenvironment to escape immune elimination
Yigit, R., Massuger, L. F. A. G., Figdor, C. G., & Torensma, R. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.01.019 · Cited by 168
Re-Education of Macrophages as a Therapeutic Strategy in Cancer
Kowal, J., Kornete, M., & Joyce, J. A. (2019) · Immunotherapy · doi:10.2217/imt-2018-0156 · Cited by 161
Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency
Cock, J. M. D., Shibue, T., Dongre, A., Keckesova, Z., Reinhardt, F., & Weinberg, R. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0608 · Cited by 160
Kitamura, T., Doughty-Shenton, D., Cassetta, L., Fragkogianni, S., Brownlie, D., Kato, Y., Carragher, N. O., & Pollard, J. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.02004 · Cited by 154
Rodriguez, G. M., Galpin, K. J. C., McCloskey, C. W., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080242 · Cited by 152
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells
Etxeberría, I., Bolaños, E., Quetglas, J. I., Gros, A., Villanueva, A., Palomero, J., Sánchez-Paulete, A. R., Piulats, J. M., Matías‐Guiu, X., Olivera, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.006 · Cited by 152
Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer
Wu, T.-C. (2008) · Biologics · doi:10.2147/btt.s1877 · Cited by 140
Chow, L. Q. M., Morishima, C., Eaton, K. D., Baik, C. S., Goulart, B. H. L., Anderson, L. N., Manjarrez, K. L., Dietsch, G. N., Bryan, J. K., Hershberg, R. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1934 · Cited by 132
Recombinant human interferon gamma therapy for osteopetrosis
Key, L. L., Ries, W. L., Rodriguiz, R. M., & Hatcher, H. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82557-0 · Cited by 114
Tumor–Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure
von Strandmann, E. P., Reinartz, S., Wager, U., & Müller, R. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.12.005 · Cited by 104
Li, Y., Wang, F., Wang, L., Huang, L. J., Wang, J., Zhang, B., & Zhang, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3547 · Cited by 95
Autio, K. A., Klebanoff, C. A., Schaer, D., Kauh, J. S. W., Slovin, S. F., Adamow, M. J., Blinder, V. S., Brahmachary, M., Carlsen, M., Comen, E. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0855 · Cited by 77
Todd, P. A., & Goa, K. L. (1992) · Drugs · doi:10.2165/00003495-199243010-00008 · Cited by 63
The current treatment of recurrent ovarian cancer
Herzog, T. J. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0074-9 · Cited by 60
Cancer cell CCR2 orchestrates suppression of the adaptive immune response
Fein, M. R., He, X., Almeida, A. S., Bružas, E., Pommier, A., Yan, R., Eberhardt, A., Fearon, D. T., Aelst, L. V., Wilkinson, J. E., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20181551 · Cited by 59
Self-citationClark, N. M., Martinez, L. M., Murdock, S. J., DeLigio, J. T., Olex, A. L., Effi, C., Dozmorov, M. G., & Bos, P. D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108482 · Cited by 51
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors
Khalil, D. N., Suek, N., Campesato, L. F., Budhu, S., Redmond, D., Samstein, R. M., Krishna, C., Panageas, K. S., Capanu, M., Houghton, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128562 · Cited by 49
Autocrine signaling of type 1 interferons in successful anticancer chemotherapy.
Vacchelli, E., Sistigu, A., Yamazaki, T., Vitale, I., Zitvogel, L., & Kroemer, G. (2015) · Europe PMC (PubMed Central) · doi:10.4161/2162402x.2014.988042 · Cited by 41
Rozenblit, M., Hendrickx, W., Heguy, A., Chiriboga, L. A., Loomis, C. A., Ray, K., Darvishian, F., Egeblad, M., Demaria, S., Marincola, F. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42784-9 · Cited by 37
Self-citationten Brinke, A., van Schijndel, G. M. W., Visser, R., de Gruijl, T. D., Zwaginga, J. J., & van Ham, S. M. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0843-z · Cited by 33
Wainberg, Z. A., Eisenberg, P. D., Sachdev, J. C., Weise, A. M., Kaufman, D. R., Hutchinson, M., Tong-Starksen, S., Aromin, I., Hu‐Lieskovan, S., & Patnaik, A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.tps465 · Cited by 21
Zhang, W., Lim, S.-M., Hwang, J., Ramalingam, S., Kim, M., & Jin, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02715-4 · Cited by 20
Lipopolysaccharide, structure and biological effects
Schultz, C. L. (2018) · General Internal Medicine and Clinical Innovations · doi:10.15761/gimci.1000152 · Cited by 12
Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model
Jallad, M.-A., Jurjus, A. R., Rahal, E. A., & Abdelnoor, A. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00839 · Cited by 9
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812774 · Cited by 972
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy
Cheng, K., Cai, N., Zhu, J., Yang, X., Liang, H., & Zhang, W. (2022) · Cancer Communications · doi:10.1002/cac2.12345 · Cited by 460
Metadata
- Authors
- Sun, L., Kees, T., Almeida, A. S., Liu, B., He, X.-Y., Ng, D., Han, X., Spector, D. L., McNeish, I. A., Gimotty, P., Adams, S., & Egeblad, M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 39
- Issue
- 10
- Pages
- 1361-1374.e9
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3197196598
- Cited by
- 267
- References
- 84
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.